Literature DB >> 28871843

Immunotherapies for advanced melanoma: as promising as they are expensive?

Livio Garattini1, Anna Padula1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28871843      PMCID： PMC5650125          DOI： 10.1177/0141076817731094

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  24 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-09-24       Impact factor: 91.245

4.  Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

Authors:  Jeffrey Weber; Geoffrey Gibney; Ragini Kudchadkar; Bin Yu; Pingyan Cheng; Alberto J Martinez; Jodie Kroeger; Allison Richards; Lori McCormick; Valerie Moberg; Heather Cronin; Xiuhua Zhao; Michael Schell; Yian Ann Chen
Journal:  Cancer Immunol Res       Date:  2016-02-12       Impact factor: 11.151

5.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Authors:  Dirk Schadendorf; F Stephen Hodi; Caroline Robert; Jeffrey S Weber; Kim Margolin; Omid Hamid; Debra Patt; Tai-Tsang Chen; David M Berman; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

6.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Authors:  N I Cherny; R Sullivan; U Dafni; J M Kerst; A Sobrero; C Zielinski; E G E de Vries; M J Piccart
Journal:  Ann Oncol       Date:  2015-05-30       Impact factor: 32.976

7.  Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.

Authors:  Claus Garbe; Ketty Peris; Axel Hauschild; Philippe Saiag; Mark Middleton; Lars Bastholt; Jean-Jacques Grob; Josep Malvehy; Julia Newton-Bishop; Alexander J Stratigos; Hubert Pehamberger; Alexander M Eggermont
Journal:  Eur J Cancer       Date:  2016-06-29       Impact factor: 9.162

Review 8.  Cancer immunotherapy: the past, the present and the future.

Authors:  Christopher R Parish
Journal:  Immunol Cell Biol       Date:  2003-04       Impact factor: 5.126

Review 9.  Cancer immunotherapy: the beginning of the end of cancer?

Authors:  Sofia Farkona; Eleftherios P Diamandis; Ivan M Blasutig
Journal:  BMC Med       Date:  2016-05-05       Impact factor: 8.775

10.  A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Authors:  Evan M Hersh; Steven J O'Day; John Powderly; Khuda D Khan; Anna C Pavlick; Lee D Cranmer; Wolfram E Samlowski; Geoffrey M Nichol; Michael J Yellin; Jeffrey S Weber
Journal:  Invest New Drugs       Date:  2010-01-16       Impact factor: 3.651
View more
  1 in total

1.  The fall and rise of the NHS.

Authors:  Kamran Abbasi
Journal:  J R Soc Med       Date:  2017-10       Impact factor: 5.344
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.